Global Healthcare Licensing: Quarterly Report

  • ID: 4451068
  • Report
  • Region: Global
  • 363 pages
  • FinGlobe, Inc
1 of 3

Japan, US and Europe are the world’s largest healthcare markets. Patients in these regions have comparable buying power and they can rely on a widely available and high quality healthcare products. As more and more progress in the life sciences sector occurs by a combination of different technologies, the growth of agreements implying activities of research and development, co-promoting and co-marketing has been strong. These licensing arrangements influence the healthcare markets and are therefore an important factor for consideration for companies for their healthcare investments.

This quarterly report brings at one place all such licensing deals and negotiations that take place between healthcare companies of Japan, US and Europe every quarter. Further, the licensing deals and negotiations that take place between healthcare companies of other select regions with Japan, US and Europe as well as among the healthcare companies of Japan, US, Europe, and other select regions every quarter are also studied and included here. Moreover, all this collected data is comprehensively analyzed to understand the licensing trends and directions during each quarter in the healthcare segments.

Key Features:

  • 3 months’ Japan-US-Europe healthcare licensing transactions at one place
  • 3 months’ other select regions healthcare licensing transactions at one place
  • Small, medium and big multinational/non-multinational companies covered
  • Curated categorizations of licensing details
  • 8+ variables reflecting different forms of transactions done
  • Licensing regulatory news updates
  • Canada/Australia/NZ licensing trends with Japan-US-Europe covered
  • Emerging markets licensing trends with Japan-US-Europe covered
  • Licensing trends among Japan, US, Europe, and other select regions covered
  • Licensing trends and directions summarized

The Report is useful to:

  • Japan, US and Europe healthcare companies planning to introduce products in each other’s markets
  • Healthcare companies of select other regions planning to introduce products in Japan, US and European markets
  • Select other regions’ healthcare companies planning to introduce products in each other’s markets
  • Companies active in R&D and seeking new market base
  • Healthcare company executives negotiating licensing deals
  • Investors analyzing varied kinds of transaction options for licensing deals
READ MORE
Note: Product cover images may vary from those shown
2 of 3

Introduction

Research Design

Section 1: Healthcare inventions licensed between Japan and United States during last quarter

1.1 By Japanese company name
1.2 By US company name
1.3 By Sub-industry
1.4 By Market capitalization groups
1.5 By Terms of payment
1.6 By medical groups

Section 2: Healthcare inventions licensed between Japan and Europe during last quarter

2.1 By Japanese company name
2.2 By Europe company name
2.3 By Sub-industry
2.4 By Market capitalization groups
2.5 By Terms of payment
2.6 By medical groups

Section 3: Healthcare inventions licensed between United States and Europe during last quarter

3.1 By US company name
3.2 By Europe company name
3.3 By Sub-industry
3.4 By Market capitalization groups
3.5 By Terms of payment
3.6 By medical groups

Section 4: Healthcare inventions licensed between Japan-US-Europe and other select regions during last quarter

4.1 Canada/Asia/Australia/NZ licensing news with Japan-US-Europe
4.2 Emerging markets licensing news with Japan-US-Europe
4.3 Undisclosed companies’ licensing news with Japan-US-Europe

Section 5: Healthcare inventions licensed within Japan, within United States and within Europe during last quarter

5.1 Japan-Japan licensing news
5.2 US-US licensing news
5.3 Europe-Europe licensing news

Section 6: Healthcare inventions licensed among countries/regions other than Japan-US-Europe during last quarter

Section 7: Quarterly trends in Japan-US-Europe and other select regions’ healthcare licensing deals

7.1 Healthcare sub-sector with most licensing deals
7.2 Countries with most licensing deals
7.3 Market Capitalization Groups with most licensing deals
7.4 Healthcare companies most active in outbound and inbound licensing deals
7.5 Medical groups most active in licensing
7.6 Licensing payment arrangements most followed
7.7 Option for increasing royalty rates
7.8 Worldwide licensing vs domestic licensing
7.9 R&D licensing vs commercialization licensing
7.10 Licensing deals which discontinued

Section 8: Trends and strategic directions

Exhibits
Exhibit 1 Summaries of healthcare inventions licensed between Japan and United States
Exhibit 2 Summaries of healthcare inventions licensed between Japan and Europe
Exhibit 3 Summaries of healthcare inventions licensed between United States and Europe
Exhibit 4 Summaries of healthcare inventions licensed between select regions and Japan-US-Europe
Exhibit 5 Summaries of healthcare inventions licensed within Japan
Exhibit 6 Summaries of healthcare inventions licensed within United States
Exhibit 7 Summaries of healthcare inventions licensed within Europe
Exhibit 8 Summaries of healthcare inventions licensed among countries/regions other than Japan-US-Europe

Appendices
Appendix 1 List of Japan-based healthcare companies covered in this report
Appendix 2 List of US-based healthcare companies covered in this report
Appendix 3 List of Europe-based healthcare companies covered in this report
Appendix 4 List of select regions’ healthcare companies covered in this report

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll